



## **Prof. Dr. Dr. Flavio Forrer**

**Leiter Nuklearmedizin**

**Leitende(r) Arzt/Ärztin**

**Radiologie und Nuklearmedizin · Dept. IV**

### **Kontakt**

Prof. Dr. Dr. Flavio Forrer  
Switzerland

T +41 71 494 2281  
flavio.forrer@kssg.ch

### **Bereiche**

Radiologie und Nuklearmedizin

### **Position**

Leiter Nuklearmedizin

### **Funktion**

Leitende(r) Arzt/Ärztin

### **Forschungsgebiet**

Radionuklidtherapie

## Publikationen (54)

Neubauer M, Nicolas G, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, Forrer F, Rentsch C, Stenner-Liewen F, Templeton A, Schäfer N, Wild D, Chirindel A, all investigators on behalf of the SSNM Therapy Working Group. Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. *Eur J Nucl Med Mol Imaging* 2023

Kratochwil C, Fendler W, Eiber M, Hofman M, Emmett L, Calais J, Osborne J, Irvani A, Koo P, Lindenberg L, Baum R, Bozkurt M, Delgado Bolton R, Ezziddin S, Forrer F, Hicks R, Hope T, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy F, Oyen W, Rahbar K, Schöder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. Joint EANM/SNMMI procedure guideline for the use of Lu-labeled PSMA-targeted radioligand-therapy (Lu-PSMA-RLT). *Eur J Nucl Med Mol Imaging* 2023; 50:2830-2845.

Forrer F, Zerdoud S, Vrachimis A, Petranovic Ovčaričekj P, Mihailovic J, Luster M, Iakovou I, Hoffmann M, Giovannella L, Maas O, Fischer G, Putora P. Variations in Radioiodine Therapy in Europe – Decision-Making after Total Thyroidectomy. *Oncology* 2021

Moreira A, Nazarenko S, Mihailovic J, Bar-Sever Z, O'Connell M, Miladinova D, Graham R, Giubbini R, Kaliská L, Rozić D, Krause B, Gallowitsch H, Györke T, Sediene S, Rumyantsev P, Wadsak W, Garcia-Cañamaque L, Simanek M, Mussalo H, Jamar F, Ozcan Z, Piciu D, Als C, Franceschi M, Trägårdh E, Zagar I, Sowa-Staszczak A, Cachin F, Bennink R, Forrer F, Adamsen T, Fotopolous A, Kalnina M, Jensen L, Kunikowska J. Impact of the COVID-19 pandemic on nuclear medicine departments in Europe. *Eur J Nucl Med Mol Imaging* 2021; 48:3361-3364.

Araf S, Fitzgibbon J, Okosun J, Johnson P, Davies A, Rimsza L, Scott D, Graham T, Barrington S, Forrer F, Kumar E, Cogliatti S, Wang J, Bewicke-Copley F, Korfi K, Fehr M. Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. *Haematologica* 2020; 105:318-321.

Weikert T, Maas O, Haas T, Klarhöfer M, Bremerich J, Forrer F, Sauter A, Sommer G. Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI. *Contrast Media Mol Imaging* 2019; 2019:1517208.

Kratochwil C, Lassmann M, Mottaghy F, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester H, Bodei L, Fanti S, Haberkorn U, Kopka K, Konijnenberg M, Kabasakal L, Fendler W, Eiber M, Baum R, Bozkurt M, Czernin J, Delgado Bolton R, Ezziddin S, Forrer F, Hicks R, Hope T, Herrmann K. EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT). *Eur J Nucl Med Mol Imaging* 2019; 46:2536-2544.

Bodei L, Modlin I, Luster M, Forrer F, Cremonesi M, Hicks R, Ezziddin S, Kidd M, Chiti A. Myeloid neoplasms after chemotherapy and PRRT: myth and reality. *Endocr Relat Cancer* 2016; 23:C1-7.

Koster-Rusch A, Capraro J, Nagel W, Clerici T, Stöckli S, Forrer F, Brändle M, Bilz S. Bilaterale Halsschwellung bei einer jungen Frau. *Swiss Medical Forum* 2016; 16:253-255.

Schwetz V, Sourij H, Treiber G, Pieber T, Forrer F, Perren A, Lackner C, Kump P, Horvath K, Mader J. Successful Medical Treatment of Adult Nesidioblastosis With Pasireotide over 3 Years: A Case Report. *Medicine (Baltimore)* 2016; 95:e3272.

Gerster-Gilliéron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas. *J Nucl Med* 2015; 56:1748-51.

Forrer F, Hirschmann M, Rasch H. SPECT/CT for the assessment of painful knee prosthesis. Nucl Med Commun 2014; 35:782.

Christ E, Reubi J, Perren A, Gloor B, Seufert J, Eil P, Stettler C, Fischli S, Clerici T, Brändle M, Caplin M, Nicolas G, Béhé M, Ederer S, Wild D, Forrer F. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol 2013; 1:115-22.

Rasch H, Falkowski A, Forrer F, Henckel J, Hirschmann M. 4D-SPECT/CT in orthopaedics: a new method of combined quantitative volumetric 3D analysis of SPECT/CT tracer uptake and component position measurements in patients after total knee arthroplasty. Skeletal Radiol 2013; 42:1215-23.

Forrer F, Oechslin-Oberholzer C, Campana B, Herrmann R, Maecke H, Mueller-Brand J, Lohri A. Radioimmunotherapy with <sup>177</sup>Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas. J Nucl Med 2013; 54:1045-52.

Forrer F, Oechslin-Oberholzer C, Campana B, Maecke H, Mueller-Brand J, Lohri A. Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab. Q J Nucl Med Mol Imaging 2012; 56:544-50.

Sommer G, Wiese M, Winter L, Lenz C, Klarhöfer M, Forrer F, Lardinois D, Brämerich J. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography/computed tomography. Eur Radiol 2012; 22:2859-67.

Giovacchini G, Nicolas G, Forrer F. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors. Anticancer Agents Med Chem 2012; 12:526-42.

Ambrosini V, Fani M, Fanti S, Forrer F, Maecke H. Radiopeptide imaging and therapy in Europe. J Nucl Med 2011; 52 Suppl 2:42S-55S.

Abiraj K, Mansi R, Tamma M, Fani M, Forrer F, Nicolas G, Cescato R, Reubi J, Maecke H. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med 2011; 52:1970-8.

Giammarile F, Luster M, Tennvall J, Borson-Chazot F, Konijnenberg M, Lambert B, Brans B, Kraeber-Bodere F, Forrer F, Flux G, Chiesa C, Bodei L, Therapy, Oncology and Dosimetry Committees. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 2011; 38:1393-406.

Wild D, Eil P, Perren A, Bomanji J, Weber W, Seufert J, Brändle M, Forrer F, Kurzwinski T, Caplin M, Christ E, Reubi J. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011; 52:1073-8.

Giovacchini G, Nicolas G, Freidank H, Mindt T, Forrer F. Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy. Eur J Nucl Med Mol Imaging 2011; 38:1675-82.

Nicolas G, Giovacchini G, Müller-Brand J, Forrer F. Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinol Metab Clin North Am 2011; 40:187-204, ix-x.

Schmid S, Myrick M, Forrer F, Obermann E, Viehl C, Rochlitz C, Güth U. Sentinel lymph node biopsy in primary breast cancer: trust the radiolabeled colloid method and avoid unnecessary procedures. *Eur J Surg Oncol* 2011; 37:211-6.

Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi J, Maecke H. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. *Eur J Nucl Med Mol Imaging* 2010; 38:97-107.

Cordier D, Forrer F, Kneifel S, Sailer M, Mariani L, Mäcke H, Müller-Brand J, Merlo A. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study. *J Neurooncol* 2010; 100:129-36.

Cordier D, Reubi J, Mäcke H, Müller-Brand J, Good S, Apostolidis C, Morgenstern A, Bruchertseifer F, Forrer F, Merlo A. Targeted alpha-radionuclide therapy of functionally critically located gliomas with <sup>213</sup>Bi-DOTA-[Thi8, Met(O2)11]-substance P: a pilot trial. *Eur J Nucl Med Mol Imaging* 2010; 37:1335-44.

Abiraj K, Mansi R, Tamma M, Forrer F, Cescato R, Reubi J, Akyel K, Maecke H. Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours. *Chemistry* 2010; 16:2115-24.

Christ E, Maecke H, Martius F, Gloor B, Clerici T, Sahli R, Brändle M, Forrer F, Wild D, Reubi J. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. *The Journal of clinical endocrinology and metabolism* 2009; 94:4398-405.

Mitchell J, Hoeijmakers J, IJzermans J, van IJcken W, de Jong M, Müller C, Forrer F, Chu T, van den Engel S, Goemaere N, van de Ven M, Brand K, Verweij M, de Bruin R. Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in mice. *Aging Cell* 2009; 9:40-53.

Eric Z, Fottner C, Forrer F, Plöckinger U, Petersenn S, Zabolotny D, Kollukch O, Yaremchuk S, Januszewicz A, Walz M, Eng C, Neumann H, Klose S, Opocher G, Rybicki L, Peçzkowska M, Golcher H, Kann P, Brauckhoff M, Müssig K, Muresan M, Schäffler A, Reisch N, Schott M, Fassnacht M, European-American Pheochromocytoma Study Group. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. *Clin Cancer Res* 2009; 15:6378-85.

Mansi R, Wang X, Forrer F, Kneifel S, Tamma M, Waser B, Cescato R, Reubi J, Maecke H. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. *Clin Cancer Res* 2009; 15:5240-9.

Forrer F, Chen J, Fani M, Powell P, Lohri A, Müller-Brand J, Moldenhauer G, Maecke H. In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. *Eur J Nucl Med Mol Imaging* 2009; 36:1443-52.

Forrer F, de Herder W, van Lom K, de Jong M, Teunissen J, Bakker W, Konijnenberg M, Bernard B, Kooij P, Krenning E, Kwekkeboom D. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. *Eur J Nucl Med Mol Imaging* 2009; 36:1138-46.

Muros M, Varsavsky M, Iglesias Rozas P, Valdivia J, Delgado J, Forrer F, Bodei L, Paganelli G. Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues. *Clin Transl Oncol* 2009; 11:48-53.

Forrer F, Riedweg I, Maecke H, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. *Q J Nucl Med Mol Imaging* 2008; 52:334-40.

Müller C, Forrer F, Schibli R, Krenning E, de Jong M. SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel <sup>99m</sup>Tc-radiofolate. *J Nucl Med* 2008; 49:310-7.

Rolleman E, Krenning E, Boerman O, Gotthardt M, Hoppin J, de Blois E, Forrer F, Breeman W, Bernard B, de Jong M. Molecular imaging of reduced renal uptake of radiolabelled [DOTA<sup>0</sup>,Tyr<sup>3</sup>]octreotate by the combination of lysine and Gelofusine in rats. *Nuklearmedizin* 2008; 47:110-5.

Melis M, Forrer F, Capello A, Bijster M, Bernard B, Reubi J, Krenning E, de Jong M. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]octreotate therapy. *Q J Nucl Med Mol Imaging* 2007; 51:324-33.

Müller C, Schibli R, Forrer F, Krenning E, de Jong M. Dose-dependent effects of (anti)folate preinjection on <sup>99m</sup>Tc-radiofolate uptake in tumors and kidneys. *Nucl Med Biol* 2007; 34:603-8.

Forrer F, Rolleman E, Schramm N, Krenning E, de Jong M. Is it possible to predict renal function in small animals using a multi-pinhole SPECT system. *Eur J Nucl Med Mol Imaging* 2007; 34:1127-8.

Forrer F, Valkema R, Kwekkeboom D, de Jong M, Krenning E. Neuroendocrine tumors. Peptide receptor radionuclide therapy. *Best Pract Res Clin Endocrinol Metab* 2007; 21:111-29.

Müller C, Forrer F, Bernard B, Melis M, Konijnenberg M, Krenning E, de Jong M. Diagnostic versus therapeutic doses of [(<sup>177</sup>Lu-DOTA-Tyr(3))-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs. *Cancer Biother Radiopharm* 2007; 22:151-9.

Forrer F, Rolleman E, Bijster M, Melis M, Bernard B, Krenning E, de Jong M. From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (<sup>99m</sup>Tc)-DMSA-SPECT and molecular imaging. *Cancer Biother Radiopharm* 2007; 22:40-9.

Rolleman E, Forrer F, Deckers J, de Groot H, Valkema R, de Jong M, Krenning E. Anaphylactoid reaction from amifostine. *Radiother Oncol* 2006; 82:110-1; author reply 111.

Rolleman E, Forrer F, Bernard B, Bijster M, Vermeij M, Valkema R, Krenning E, de Jong M. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]octreotate. *Eur J Nucl Med Mol Imaging* 2006; 34:763-771.

Forrer F, Valkema R, Bernard B, Schramm N, Hoppin J, Rolleman E, Krenning E, de Jong M. In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals. *Eur J Nucl Med Mol Imaging* 2006; 33:1214-7.

Forrer F, Waldherr C, Maecke H, Mueller-Brand J. Targeted radionuclide therapy with <sup>90</sup>Y-DOTATOC in patients with neuroendocrine tumors. *Anticancer Res* 2006; 26:703-7.

Schiavi F, Välimäki M, Kawecki A, Szutkowski Z, Schipper J, Walz M, Pigny P, Bauters C, Willet-Brozick J, Baysal B, Januszewicz A, Eng C, Opocher G, Neumann H, Forrer F, Walter M, Boedeker C, Bausch B, Peçzkowska M, Gomez C, Strassburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann M, Berlis A, Brink I, Cybulla M, Muresan M, European-American Paraganglioma Study Group. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. *JAMA* 2005; 294:2057-63.

Forrer F, Uusijärvi H, Storch D, Maecke H, Mueller-Brand J. Treatment with <sup>177</sup>Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with <sup>90</sup>Y-DOTATOC. *J Nucl Med* 2005; 46:1310-6.

Forrer F, Mueller-Brand J, Maecke H. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours. *Eur J Nucl Med Mol Imaging* 2005; 32:511-2; author reply 513.

Forrer F, Uusijärvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, Maecke H. A comparison of <sup>111</sup>In-DOTATOC and <sup>111</sup>In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. *Eur J Nucl Med Mol Imaging* 2004; 31:1257-62.

Hoffmann-Richter U, Forrer F, Finzen A. [Schizophrenia in the German national paper *Frankfurter Allgemeine Zeitung* -- a didactic play]. *Psychiatr Prax* 2003; 30:4-7.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)